Post-treatment Serum Autotaxin and Subsequent Hepatocellular Carcinoma Development During Nucleos(t)ide Analog Therapy for Chronic Hepatitis B: An Exploratory Study
Objective The risk of hepatocellular carcinoma (HCC) persists despite nucleos(t)ide analog (NA) therapy in patients with hepatitis B virus (HBV) infection. We investigated whether post-treatment serum autotaxin (ATX), a noninvasive fibrosis-related biomarker, is associated with subsequent HCC development during NA therapy.Methods We measured the serum ATX levels at baseline and at week 48 of NA therapy. Patients were followed for HCC development. The optimal ATX cutoff value was determined using a receiver operating characteristic (ROC) curve analysis, and cumulative HCC incidence was evaluated using the Kaplan-Meier method.Patients This retrospective single-center cohort study included 67 treatment-naïve patients with chronic hepatitis B who received NA therapy for at least 48 weeks.Results The median age was 59 years, and 58.2% of the patients were men. During a median follow-up period of 6.3 years, five patients developed HCC. The serum ATX levels decreased significantly after 48 weeks of NA therapy (0.93 vs. 0.84 mg/L, P < 0.001). Patients who subsequently developed HCC had significantly higher post-treatment ATX levels than those who did not (1.32 vs. 0.84 mg/L, P = 0.010). Among the evaluated fibrosis-related biomarkers, ATX showed the highest discriminative ability for HCC development, with an area under the receiver operating characteristic curve of 0.90. With an ATX/upper limit of normal ratio cutoff of 0.92, patients with elevated ATX levels that showed a significantly higher cumulative incidence of HCC than those with lower levels (10-year incidence: 25.0% vs. 1.96%, log-rank P = 0.001).Conclusions The serum ATX levels decreased after NA therapy, but remained elevated in patients who subsequently developed HCC. Validation of these preliminary findings in larger prospective cohorts is needed.
Authors
- 浩二 五十嵐
- Shun‐ichi Wakabayashi (ORCID: https://orcid.org/0000-0002-4657-4785)
- Taiki Okumura (ORCID: https://orcid.org/0000-0001-5715-1748)
- Tomoo Yamazaki (ORCID: https://orcid.org/0000-0001-6958-1366)
- Takefumi Kimura (ORCID: https://orcid.org/0000-0002-1481-1029)
- Naoki Tanaka (ORCID: https://orcid.org/0000-0003-0962-2183)
- Kaede Fujita (ORCID: https://orcid.org/0009-0002-8286-2159)
- Satoshi Shimamoto
- Yuma Kamijo
- Takanobu Iwadare
- Hiroaki Sekita
- Hiroyuki Kobayashi
Institutions
- Shinshu University (JP)
- Shinshu University Hospital (JP)
- Tosoh (Japan) (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.2169/internalmedicine.8073-26
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science